2. Academic Validation
  3. EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer

EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer

  • Oncogene. 2020 Oct;39(44):6757-6775. doi: 10.1038/s41388-020-01468-9.
Shian-Ren Lin  # 1,  Yu-Ching Wen  # 2 3,  Hsiu-Lien Yeh 4,  Kuo-Ching Jiang 1,  Wei-Hao Chen 1,  Ntlotlang Mokgautsi 1,  Jiaoti Huang 5,  Wei-Yu Chen 6 7,  Yen-Nien Liu 8 9
Affiliations

Affiliations

  • 1 Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
  • 2 Department of Urology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
  • 3 Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • 4 Institute of Information System and Applications, National Tsing Hua University, Hsinchu, Taiwan.
  • 5 Department of Pathology, Duke University Medical Center, Durham, NC, USA.
  • 6 Department of Pathology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. 1047@tmu.edu.tw.
  • 7 Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. 1047@tmu.edu.tw.
  • 8 Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan. liuy@tmu.edu.tw.
  • 9 Department of Pathology, Duke University Medical Center, Durham, NC, USA. liuy@tmu.edu.tw.
  • # Contributed equally.
PMID: 32963351 DOI: 10.1038/s41388-020-01468-9
Abstract

Neuroendocrine (NE) differentiation is a well-recognized phenotypic change of prostate Cancer after androgen deprivation therapy (ADT), and it ultimately develops into an aggressive subset of this disease. However, the contribution of signaling pathways that lead to metabolic disorders and NE differentiation of prostate Cancer remains unclear. In this study, we identified that ADT induced upregulation of the succinate-CoA Ligase GDP-forming beta subunit (SUCLG2), which regulates succinate metabolism and NE differentiation of prostate Cancer. We demonstrated a connection that upregulation of epidermal growth factor receptor (EGFR)-leukemia inhibitory factor receptor (LIFR) signaling induced SUCLG2 expression in prostate Cancer cells. The LIFR is upregulated by nuclear EGFR, which acts as a transcriptional regulator, directly binds to the LIFR promoter, and drives NE differentiation and glycolysis of prostate Cancer. LIFR upregulation is associated with SUCLG2, which increased succinate synthesis and enzymatic activities of mitochondrial nucleoside diphosphate kinase (NDPK) in prostate Cancer cells. Knockdown of SUCLG2 suppressed NE differentiation in cultured cells and reduced prostate tumor growth in a xenograft model. Analysis of prostate tissue samples showed increased intensity of nuclear EGFR associated with the LIFR and SUCLG2 in castration-resistant prostate Cancer tumors. Our study provides a mechanism whereby ADT upregulates EGFR-LIFR signaling that activates SUCLG2, which subsequently stimulates the metabolic changes associated with NE differentiation and aggressive prostate Cancer phenotype.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-100949
    99.60%, LIF 抑制剂
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z